Why Diamyd Medical stock moves
Diamyd Medical was roughly unchanged, without company news.
Written after the close on ·
Why today
16,416 news analyzed todayDiamyd Medical was roughly unchanged, without company news.
Diamyd Medical was roughly unchanged, while OMX Stockholm 30 fell clearly, so it moved less than the market.
The move was an ordinary one for the stock, within its usual daily range.
No company news explains the session.
Over the last five trading days the shares fell slightly, while OMX Stockholm 30 was roughly flat.
Today's move of −0.31% was 0.3 times a normal day's 1.0%. OMX Stockholm 30 moved −1.01% on the same day.
Diamyd Medical −0.31%OMX Stockholm 30 −1.01%A little stronger than the market
Has the share price followed the business?
Price and earnings moved in the same direction: 1 out of 3 years. Across Nordic companies, that happens in about 60% of years. In 2026, the price changed −91% and earnings per share went from -1.50 SEK to -1.80 SEK.
Revenue, profit and market cap
RevenueProfitMarket capbn SEK
Assets, liabilities and market cap
AssetsLiabilitiesMarket capbn SEK
Price and earnings moved in the same direction: 1 out of 3 years.Market cap (Now): 151 m SEKRevenue 2026: 0.5 m SEK
What the key figures say about Diamyd Medical
The figures connect what Diamyd Medical earns with what investors pay.
The line shows the share price in the same year, on its own scale.
Profit divided by the number of shares. Each share represents this much of the earnings.
2023–2026: -1.80 SEK–-1.49 SEK. Peers: Initiator Pharma -0.60 SEK, Active Biotech -1.70 SEK, Intervacc -0.26 SEK.
What the company sold during the year.
2023–2026: 0.1 m SEK–0.5 m SEK. Peers: Intervacc 18.1 m SEK.
The percentage of revenue left after the costs of running the business.
2023–2026: −113287.7%–−21217.2%. Peers: Intervacc −519.8%.
Profit as a percentage of shareholders’ money in the company.
2023–2026: −104.9%–−60.6%. Peers: Initiator Pharma −336.2%, Active Biotech −140.6%, Intervacc −32.9%.
What investors pay for each unit the company sells.
2023–2026: 332.02–12,654.49. Peers: Intervacc 14.64.
More key figures
Market cap divided by shareholders’ equity, what remains after liabilities.
2023–2026: 0.65–11.27. Peers: Active Biotech 1.71, Intervacc 1.14.
Cash left after investments, divided by the number of shares.
2023–2026: -1.42 SEK–-1.27 SEK. Peers: Initiator Pharma -0.34 DKK, Active Biotech -1.23 SEK, Intervacc -0.22 SEK.
The percentage of assets financed by shareholders’ equity.
2023–2026: 66.7%–82.3%.
What to watch next, and why
The earnings report shows how Diamyd Medical's revenue and profit have changed.
- Earnings report
The earnings report shows how Diamyd Medical's revenue and profit have changed.
Add to calendar
People on the board and in management must report their trades in the share to Finansinspektionen, Sweden's financial supervisor. November 2: Buy about 10 thousand SEK. July 27: Buy about 98 thousand SEK. June 24: Buy about 100 thousand SEK. April 29: Buy about 104 thousand SEK. April 28: Buy about 210 thousand SEK.
More about Diamyd Medical
Insider trades
People on the board and in management must report their trades in the share to Finansinspektionen, Sweden's financial supervisor.
- Mathias Skalmstad, CFOBuyabout 10 thousand SEK
- Anders Essen-Möller, CEOBuyabout 98 thousand SEK
- Anders Essen-Möller, CEOBuyabout 100 thousand SEK
- Anders Essen-Möller, CEOBuyabout 104 thousand SEK
- Anders Essen-Möller, CEOBuyabout 210 thousand SEK
Earnings report
Next report: · Add to calendar · Google Calendar
On its last 16 report days Diamyd Medical usually moved about 2.5%. On a normal day it moves 1.0%.
−5.80% −8.55% −8.19% +11.93%
10,000 SEK in Diamyd Medical bought on November 7, 2016 is worth 1,700 SEK today, with dividends reinvested.
What would 10,000 SEK in Diamyd Medical be worth today? →
What would 10,000 SEK in Diamyd Medical be worth today?
1,700 SEK
with dividends reinvested, bought on November 7, 2016.
At worst it was worth 1,640 SEK (October 7, 2026).
The five biggest days of the journey
· −89.4% · the whole market rose 0.9% the same day
· +61.9% · the whole market rose 0.1% the same day
· +44.2% · the whole market rose 0.7% the same day
· +40.7% · the whole market rose 2.2% the same day
· +38.3% · the whole market was unchanged the same day
Earlier days
−1.91% market −0.11% Diamyd Medical fell slightly over the week while the broader market was roughly flat. Read →
Diamyd Medical fell slightly over the week while the broader market was roughly flat.
Trading was thin, so the move reflects a quiet week rather than a strong new driver.
The next scheduled event is the earnings report on 1 January 2027.
−1.71% market −0.32% Diamyd Medical fell clearly without a company-news explanation. Read →
Diamyd Medical fell clearly without a company-news explanation.
The stock fell slightly over the last five trading days, moving against a slightly rising OMX Stockholm 30.
The fall was larger than the market's slight decline that same session.
The session's move was within its usual daily range, so it was an ordinary day for the stock.
Trading volume was well below its usual level, so the move happened on thin trading.
+0.71% market +0.83% Diamyd Medical rose, moving in line with the market. Read →
Diamyd Medical rose, moving in line with the market.
No company news explains the move.
Over the last five trading days it also rose slightly, matching OMX Stockholm 30.
The move was an ordinary one for the stock, with thin trading.
−1.00% market −0.08% Diamyd Medical fell slightly without a company-news explanation. Read →
Diamyd Medical fell slightly without a company-news explanation.
Over the same session, OMX Stockholm 30 was roughly flat, so the stock moved while the broader market stayed steady.
The move was an ordinary-sized one for Diamyd Medical, within its usual daily range.
Over the last five trading days the stock was roughly unchanged, while the OMX Stockholm 30 rose slightly, so it lagged the market a little.
The most recent company items are dated background: the board's proposed re-election, and the notice for the annual general meeting on Thursday, 3 December 2026.
+0.40% market +0.48% Diamyd Medical was roughly unchanged. Read →
Diamyd Medical was roughly unchanged.
Over the same day, OMX Stockholm 30 rose slightly, so Diamyd Medical moved less than the market.
The move was an ordinary one for this stock.
No company news from that session explains it.
Over the last five trading days the shares were roughly unchanged, while the market rose clearly.
−1.39% market +3.01% Diamyd Medical fell slightly over the week, while the OMX Stockholm 30 index rose clearly, so it moved against the market. Read →
Diamyd Medical fell slightly over the week, while the OMX Stockholm 30 index rose clearly, so it moved against the market.
The move was ordinary for the stock, and trading stayed around its usual level.
Company news was limited: board nominations and the notice for the annual general meeting were published, and neither clearly explains the decline.
The wider Healthcare group on Nasdaq First North Sweden also fell noticeably over the same days, so sector weakness may have contributed.
+2.45% market +0.41% Diamyd Medical rose clearly, more than the market. Read →
Diamyd Medical rose clearly, more than the market.
The notice of its annual general meeting on 3 December came out that day.
Over the last five trading days the shares were roughly unchanged, while OMX Stockholm 30 rose sharply.
Trading was about three times a normal day, and the price sits well below its high of early February.
The AGM notice is the most likely reason, though the rise is only partly explained by it.
−1.00% market +0.96% Diamyd Medical fell slightly. Read →
Diamyd Medical fell slightly.
No company news explains the move.
Over the last five trading days the shares fell slightly while OMX Stockholm 30 was roughly flat.
Peers in the sector fell more sharply over the same days, which may partly reflect sector-wide selling.
The move was an ordinary one for this stock.
−0.99% market +1.57% Diamyd Medical traded slightly lower, moving against a rising market. Read →
Diamyd Medical traded slightly lower, moving against a rising market.
Over the last five trading days it fell slightly, in line with the market.
The move was ordinary for the stock and no company news explains it.
The only item is an estimates update from Friday, which was known before the session opened.
Trading volume was well above its usual level.
−7.34% market −3.67% Diamyd Medical fell clearly over the last five trading days, more than the broader Stockholm market, which also fell sharply. Read →
Diamyd Medical fell clearly over the last five trading days, more than the broader Stockholm market, which also fell sharply.
The move was big for this stock, roughly double a normal five-day stretch, and comparable moves were rare in the past year.
Watch for the next company report and any new analyst rating changes.
−0.98% market −2.51% Diamyd Medical edged down without company news. Read →
Diamyd Medical edged down without company news.
The market fell sharply, so the stock held up better than OMX Stockholm 30.
Over the last five trading days the shares were roughly unchanged while the market fell clearly.
The move was an ordinary one for the stock and trading was quiet.
−6.97% market −0.89% Diamyd Medical fell sharply without company news explaining it. Read →
Diamyd Medical fell sharply without company news explaining it.
Over the last five trading days, the share was roughly unchanged, in line with a flat OMX Stockholm 30.
In the last session the share fell much more than the market, which fell clearly.
The likely driver is the broader selloff in the market, with Diamyd Medical falling harder, and trading was thin, so price moves can be exaggerated.
Learn more · Why do stocks go up and down?